Cedar Creek Partners Q3 2026 Portfolio Update

Fairfax owns more than 49% of Exco Resources, a primarily domestic onshore natural gas producer. The speaker says nothing has changed at PD-Rx Pharmaceuticals, notes the position has been shrinking, and hopes management will sell the business. Pennsylvania Warehousing and Safe Deposit Company is described as very illiquid, with 3,251 shares outstanding.

Analysis

The investable question is not the operating story of these holdings, but their materiality to Fairfax’s per-share value and whether they can be monetized. Exco creates a possible natural-gas-price sensitivity within the portfolio; without its carrying value, valuation basis, and Fairfax’s accounting treatment, it is not possible to infer a meaningful change in FFH’s NAV or earnings. A sale of PD-Rx could release capital, but the article provides no evidence of a buyer, timing, or proceeds. Pennsylvania Warehousing’s stated share scarcity is a liquidity constraint, not evidence of realizable value: any quoted price may be a poor proxy for Fairfax’s exit value.

Near term, these details alone are unlikely to support a trade in FFH. Over the next 1–3 months, monitor Fairfax disclosures for a transaction, valuation change, or updated investment carrying values. Over 6–18 months, Exco’s value could move with gas prices and operating performance, but that exposure should not be extrapolated to Fairfax’s broader business. The thesis changes only if disclosed proceeds or valuation revisions are material relative to FFH’s investment portfolio/NAV. No clear consensus mispricing or near-term catalyst is established here.

Key Decisions for Investors

• No standalone FFH position change on this information; treat the holdings commentary as an alert, not a catalyst.
• Before assigning value to Exco, verify Fairfax’s reported carrying value, ownership/accounting treatment, and any disclosed production or realized-price sensitivity. Reassess if those disclosures imply a material NAV contribution.
• Track PD-Rx for a signed sale and reported proceeds; absent transaction evidence, do not price in a recovery from a possible disposal.
• Do not use Pennsylvania Warehousing’s share count or any sparse quote as an exit valuation. Require disclosed transaction evidence or credible valuation data before incorporating a realizable-value uplift.